Prolia
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
AIM
To evaluate the efficiency and safety of long-term Prolia therapy in patients with postmenopausal osteoporosis (OP…
Background Prolia has marketing authorization in the EU, US, Canada, Japan, and over 40 countries or administrative districts…
Background Prolia® (denosumab) has shown to be a safe and efficacious therapy for osteoporotic patients in numerous clinical…
Prolia is an expensive method of preventing osteoporotic hip fractures, and is associated with significant adverse effects. Safer…